NextCure (NXTC) Stock Price, News & Analysis

Company Overview

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Key Stats

• Today's Range: $0.42 to $0.48
• 50-Day Range: $0.38 to $0.68
• 52-Week Range: $0.22 to $1.82
• Volume: 94,400 shs
• Average Volume: 127,470 shs
• Market Capitalization: $12.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Buy

NextCure Stock Analysis - MarketRank™

NextCure scored higher than 84% of companies evaluated by MarketBeat, and ranked 179th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NextCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NextCure has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NextCure are expected to grow in the coming year, from ($1.87) to ($1.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NextCure is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NextCure is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NextCure has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.22% of the float of NextCure has been sold short.

Short Interest Ratio / Days to Cover

NextCure has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NextCure has recently increased by 266.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NextCure does not currently pay a dividend.

Dividend Growth

NextCure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.08

Percentage of Shares Shorted

1.22% of the float of NextCure has been sold short.

Short Interest Ratio / Days to Cover

NextCure has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NextCure has recently increased by 266.67%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for NextCure this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added NextCure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NextCure insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.30% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NXTC Stock Analysis - Frequently Asked Questions

How have NXTC shares performed this year?

NextCure's stock was trading at $0.7710 on January 1st, 2025. Since then, NXTC shares have decreased by 40.9% and is now trading at $0.4556.

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) released its quarterly earnings results on Thursday, May, 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01.

When did NextCure IPO?

NextCure (NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

How do I buy shares of NextCure?

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NXTC
• CIK: 1661059
• Web: www.nextcure.com
• Phone: (240) 399-4900
• Fax: N/A
• Employees: 90
• Year Founded: 2015

Price Target and Rating

• Average Price Target for NextCure: $3.50
• High Price Target: $4.00
• Low Price Target: $3.00
• Potential Upside/Downside: +668.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.16%
• Return on Assets: -58.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.26
• Quick Ratio: 10.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.34 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 28,050,000
• Free Float: 24,319,000
• Market Cap: $12.78 million
• Optionable: Optionable
• Beta: 1.06